POINT BIOPHARMA GLOBAL INC. Revenue
POINT BIOPHARMA GLOBAL INC. reported Revenue of $2.79 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2023-11-13
- POINT BIOPHARMA GLOBAL INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-09-30 was $2.79M.
- POINT BIOPHARMA GLOBAL INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-06-30 was $4.87M.
- POINT BIOPHARMA GLOBAL INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-03-31 was $9.46M.
- POINT BIOPHARMA GLOBAL INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $226.58M.
- POINT BIOPHARMA GLOBAL INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $226.58M.
- POINT BIOPHARMA GLOBAL INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.79M 10-Q · filed 2023-11-13 | $7.66M derived: sum of 2 quarters · filed 2023-11-13 | $17.11M 10-Q · filed 2023-11-13 | $243.69M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | $4.87M 10-Q · filed 2023-08-14 | $14.32M 10-Q · filed 2023-08-14 | $240.90M derived: sum of 3 quarters · filed 2023-08-14 | $240.90M derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-03-31 | $9.46M 10-Q · filed 2023-05-15 | $236.04M derived: sum of 2 quarters · filed 2023-05-15 | $236.04M derived: sum of 3 quarters · filed 2023-11-13 | $236.04M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-12-31 | $226.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $226.58M derived: sum of 2 quarters · filed 2023-11-13 | $226.58M derived: sum of 3 quarters · filed 2023-11-13 | $226.58M 10-K · filed 2023-03-27 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-27 |